Health Condition 1: I504- Combined systolic (congestive) anddiastolic (congestive) heart failure
Conditions
Interventions
Intervention1: Growth Hormone: To be given in growth hormone deficient chronic heart failure patient
Subject will be receive growth hormone in a dose of 0.012 mg/kg every second day (approx. 2.5 IU),
Sponsors
Indian Council Of Medical Research
Eligibility
Inclusion criteria
Inclusion criteria: 1. Elderly patients, =60and =90 years of age, in outpatient and inpatients, who have 2. Chronic heart failure (with both preserved and reduced ejection fraction) with The New York Heart Association (NYHA) class 2 to 4 irrespective of etiology and whose treatment has not been modified in the past 4 weeks. 3. Patients having growth hormone deficiency 4. Patients are willing to provide written informed consent.
Exclusion criteria
Exclusion criteria: 1. Active proliferative or severe non-proliferative diabetic retinopathy, 2.Active malignancy, 3. Any evidence of progression or recurrence of an underlying intracranial tumour 4 Recent myocardial infarction, 5. Severe liver disease, and 6. Serum creatinine levels greater than 2.5 mg/dl.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| echocardiography in improved ejection fraction (in patients with HFrEF), change in end systolic volume from baseline, LV end diastolic dimension and change in relative wall thickness as a prognostic marker for disease progression Change in functional capacity assessment Blood levels of NT-proBNP Improvement in NYHA classTimepoint: 0,90,180,365 days | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in quality-of-life Change in frailty assessment score Sarcopenia assessment Timepoint: 0,90,180,365 days | — |
Countries
India
Contacts
Public ContactMukesh Kumar
Government Institute of Medical Sciences
Outcome results
None listed